Glenmark Pharmaceuticals Ltd


Glenmark Pharmaceuticals Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)614.15
  • Today's Change4.40 / 0.72%
  • Shares traded770.39k
  • 1 Year change+57.68%
  • Beta1.0862
Data delayed at least 15 minutes, as of Jun 02 2023 11:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Key statistics

On Friday, Glenmark Pharmaceuticals Ltd (GLENMARK:NSI) closed at 614.15, -2.49% below its 52-week high of 629.85, set on May 19, 2023.
52-week range
348.50Jun 20 2022629.85May 19 2023
Previous close614.15
Average volume1.75m
Shares outstanding282.17m
Free float134.99m
P/E (TTM)58.32
Market cap173.29bn INR
EPS (TTM)10.53
Annual div (ADY)2.50
Annual div yield (ADY)0.41%
Div ex-dateSep 12 2022
Div pay-dateOct 27 2022
Data delayed at least 15 minutes, as of Jun 02 2023 11:10 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.